Vertex Pharmaceuticals Inc. (VRTX) announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study assessing the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus or HCV infection who have the IL28B CC genotype. In the study, telaprevir was administered twice daily in combination with pegylated-interferon and ribavirin.
Of the 239 people in the study, 159 people completed 12 weeks of telaprevir combination treatment and had undetectable hepatitis C virus at week four of treatment and were eligible to be randomized.
In the 12-week total treatment group, of the 85 people with data available at the time of the interim analysis, 87 percent had undetectable hepatitis C virus 12 weeks after the end of treatment or SVR12. In the 24-week treatment group, of the 30 people with data available at the time of the interim analysis, 97 percent achieved SVR12. This trial includes people with genotype 1 chronic HCV who were new to treatment or who had relapsed after at least one prior course of treatment with pegylated-interferon and ribavirin alone.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.